<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631066</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx180.000</article-id><article-id pub-id-type="publisher-id">ofx180.000</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Late Breaker Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>A Randomized Trial of High-dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Natori</surname><given-names>Yoichiro</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Humar</surname><given-names>Atul</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Shiotsuka</surname><given-names>Mika</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Slomovic</surname><given-names>Jaclyn</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Hoschler</surname><given-names>Katja</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Victor</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Ashton</surname><given-names>Peter</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Rotstein</surname><given-names>Coleman</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Lilly</surname><given-names>Les</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Schiff</surname><given-names>Jeffrey</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Singer</surname><given-names>Lianne</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Deepali</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Transplant Infectious Diseases, University Health Network</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country>;</aff><aff id="AF0002">
<label>2</label>
<institution>Transplantation, University of Toronto</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country>;</aff><aff id="AF0003">
<label>3</label>
<institution>University Health Network</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country>;</aff><aff id="AF0004">
<label>4</label>
<institution>Public Health England</institution>, <addr-line>London</addr-line>, <country>UK</country>;</aff><aff id="AF0005">
<label>5</label>
<institution>UHN</institution>, <addr-line>Toronto, ON</addr-line>, <country>Canada</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 228. Late Breaker Oral Abstracts</p><p>
<italic>Saturday, October 7, 2017: 10:30 AM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S734</fpage><lpage>S734</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx180.000.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The annual influenza vaccine is recommended for solid-organ transplant recipients (SOTR) although studies have shown suboptimal immunogenicity. Influenza vaccine containing higher dose antigen may lead to greater immunogenicity in this population.</p></sec><sec id="s2"><title>Method</title><p>We conducted a randomized, observer-blind trial comparing the safety and immunogenicity of high dose (HD; FluzoneHD, Sanofi) vs. standard dose (SD; Fluviral, GSK) influenza vaccine in adult SOTR. Patients were randomized 1:1 to receive the 2016&#x02013;2017 influenza vaccine. Preimmunization and 4-week postimmunization sera underwent strain-specific hemagglutination inhibition assay for the three vaccine strains and an additional B strain not included in the vaccine.</p></sec><sec id="s3"><title>Result</title><p>We randomized 172 patients and 161 (84 HD; 77 SD) were eligible for analysis. Median age was 57&#x000a0;years (range 18&#x02013;86) and time from transplant was 38 (range 3&#x02013;1402) months. Types of transplant were kidney 67 (39.0%), liver 38 (22.1%), lung 25 (14.5%), heart 23 (13.3%), and combined 19 (11.0%). Seroconversion to at least one of the three vaccine antigens (primary outcome) was present in 78.6% vs. 55.8% in HD vs. SD vaccine, respectively (<italic>P &#x0003c;</italic> 0.001). Seroconversion to A/H1N1, A/H3N2, and B strains were 40.5% vs. 20.5%, 57.1% vs. 32.5%, and 58.3% vs. 41.6% in HD vs. SD vaccine (<italic>P =</italic> 0.006, 0.002, 0.028, respectively). Postimmunization geometric mean titers of A/H1N1, A/H3N2, and B strains were significantly higher in the HD group &#x02028;(<italic>P =</italic> 0.007, 0.002, 0.033). Independent factors associated with seroconversion to at least one vaccine strain were the use of HD vaccine and being on mycophenolate doses less than 2&#x000a0;g daily (<italic>P =</italic> 0.003, 0.013, respectively). Seroconversion rate to the B strain not included in the trivalent study vaccine was also higher in the HD vaccine group (33.3% vs. 14.1%, <italic>P =</italic> 0.004). Local and systemic adverse events were similar for the two vaccines. Biopsy-proven rejection was seen in 3.4% vs. 1.2% in HD vs. SD groups, respectively (<italic>P =</italic> 0.62). Two patients in the SD vaccine group and one in the HD group developed influenza infection during the follow-up.</p></sec><sec id="s4"><title>Conclusion</title><p>High-dose vaccine demonstrated significantly better immunogenicity than SD vaccine in adult transplant recipients and may be the preferred influenza vaccine for this population.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>D.&#x000a0;Kumar</bold>, Sanofi: Speaker&#x02019;s Bureau, Speaker honorarium. Pfizer: Speaker&#x02019;s Bureau, Speaker honorarium. GSK: Grant Investigator, Grant recipient.</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>